Stocktoria
Enliven Therapeutics, Inc. ELVN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-03-12
Enliven Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D expense | $85.9M | $80.8M | $64.6M | $31.0M | $38.4M | $32.2M | $19.0M |
| Operating income | -$119.7M | -$104.6M | -$83.5M | -$38.8M | -$51.4M | -$41.7M | -$24.1M |
| Income tax | $0 | $232,000 | $0 | $0 | — | — | — |
| Net income | -$103.7M | -$89.0M | -$71.6M | -$37.7M | -$51.4M | -$41.4M | -$23.5M |
| EPS (diluted) | $-1.83 | $-1.89 | $-2.01 | $-12.05 | $-2.37 | — | — |
| Operating cash flow | -$70.3M | -$73.2M | -$61.3M | -$32.1M | -$46.8M | -$37.4M | -$21.9M |
| Cash & equivalents | $98.9M | $124.1M | $100.1M | $75.5M | $48.3M | $47.7M | $4.9M |
| Total assets | $476.2M | $325.8M | $271.9M | $83.3M | $93.6M | $90.8M | $33.3M |
| Total liabilities | $16.6M | $15.9M | $26.0M | $10.4M | $7.6M | $6.4M | $4.4M |
| Shareholders' equity | $459.6M | $309.8M | $245.9M | -$76.8M | -$42.9M | $84.4M | -$48.8M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.